Nektar Therapeutics (NKTR) Misses Q2 EPS by 6c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $73.76 -3.42%
Revenue Growth %: -11.4%
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
PMCB, CULP, HURC, More
Revenue Growth %: -11.4%
Financial Fact:
Income (loss) from operations: -32.9M
Today's EPS Names:
PMCB, CULP, HURC, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q2 EPS of ($0.25), $0.06 worse than the analyst estimate of ($0.19). Revenue for the quarter came in at $23.5 million versus the consensus estimate of $20.63 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Dell’s earning report was bullish for Intel CPU demand, analyst says
- SK Hynix (SKHY) call put ratio 1.4 calls to 1 put as share price up 3.8%
- StoneX Reiterates Hold Rating on Old Dominion Freight Line (ODFL) on QTD Operating Metrics
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
